Preclinical trials also demonstrated that TNF inhibitors could effectively alleviate amyloid pathology and tau phosphorylation [96], while clinical studies demonstrated the potential of etanercept, another TNF inhibitor, to improve language performance in a small cohort of AD subjects, although its full therapeutic effect remains to be validated [97,98]. This evidence concerns the gene TNF and Alzheimer disease.